



Alpa Laboratories Ltd.

33/2, A.B. Road, Pigdamber-453446, Distt. Indore (M.P.) India
Phone No : +91-731-429 4567 Fax No : +91-731-429 4444, E-mail: cs@alpalabs.in
CIN-L85195MP1988PLC004446

Date: - 11th February, 2026

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051
Scrip Code: ALPA

Listing Department,
Bombay Stock Exchange Limited.
Rotunda Building, P J Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 532878

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is with reference to our letter dated 29th January, 2026 in relation to intimation of Board Meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 11:00 A.M at Registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for the Quarter ended on 31st December, 2025 with Limited Review Report from the Statutory Auditor of the Company.


This is for the information and record of the exchange and members thereof.

The Meeting commenced at 11:00 AM and concluded at 12:05 PM.

You are requested to take the same on records.

Thanking you,
Yours faithfully,

FOR ALPA LABORATORIES LIMITED


Srashti Chopra
Company Secretary



C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F. C. A.

VIPUL PADLIYA B. Com., F. C. A.



H.O. : 90, Dawa Bazar, 2nd Floor, 13-14
RNT Marg, Indore - 452 001 (INDIA)
Office : +91 731 2704343

B.O. : 101, Pragati Appartment, Opp. Krashi
Mandi, Pratapnagar (Raj.)-312605

Tel. : +1478-22624

Official webpage : www.chpadliya.com

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review report to the Board of Directors of **ALPA LABORATORIES LIMITED**,

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **ALPA LABORATORIES LIMITED** ("the Company") for the quarter ended **31st December, 2025**, and year to date results for the period 1st April, 2025 to 31st December, 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Listing Regulations) including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of

C.H. PADLIYA & Co.

Chartered Accountants

Firm registration no.003151C

S.C. PADLIYA

Partner

Membership No.071666

UDIN: 26071666BJARCB9300

Date: 11th Day of February, 2026

Place: Indore





Alpa Laboratories Ltd.

33/2, A B Road, Pigdamber-453446, Distt. Indore (M.P.) India
Phone No. +91-731-429 4567 Fax No. +91-731-429 4444. E-mail: ca.alpalabs@gmail.com
CIN-LB5195MP1988PLC004446

Financial Results for Quarter and Nine Months ended 31st December, 2025 (Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone

Particulars	Standalone Results					
	Quarter Ended			Nine Months Ended		Year Ended
	Dec-25	Sep-25	Dec-24	Dec-25	Dec-24	Mar-25
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a) Revenue from operations	2,967.12	2,563.21	2,615.02	7,441.40	7,253.26	11,164.49
b) Other Income	26.05	368.61	880.17	1,590.44	2,087.15	2,411.22
Total income from operations	2,993.17	2,931.82	3,495.19	9,031.84	9,340.41	13,575.71
2. Expenses						
a) Cost of materials consumed	1,816.08	1,655.16	1,273.98	4,665.58	3,905.93	7,071.93
b) Purchases of stock-in-trade	2.07	1.16	48.42	3.23	90.73	93.11
c) Changes in inventories of finished products, work in progress and stock in trade	128.44	325.73	127.98	359.01	256.57	(145.22)
d) Employee benefit expenses	371.79	362.05	336.11	1,076.37	1,005.66	1,436.76
e) Finance costs	3.14	4.61	10.11	13.01	21.61	26.63
f) Depreciation and amortization expense	64.65	67.15	55.05	187.13	162.12	220.24
g) Other expenses						
Manufacturing & Operating	191.48	179.52	167.63	540.48	477.00	626.69
Others	243.63	326.31	586.60	827.42	1,061.63	1,661.45
Total expenses	2,821.27	2,921.69	2,605.89	7,672.22	6,981.25	10,991.59
3. Profit/(Loss) before exceptional items and tax (1-2)	171.89	10.13	889.30	1,359.61	2,359.16	2,584.12
4. Exceptional Items	-	-	-	-	3.69	-
5. Profit/ Loss(-) before tax (3+/-4)	171.89	10.13	889.30	1,359.61	2,362.85	2,584.12
6. Tax (Expenses)/ Benefit						
Current tax	(15.59)	-	-	(15.59)	196.43	(406.43)
Deferred Tax	-	-	-	-	-	(209.75)
Tax Related to Earlier Years	-	-	-	-	-	-
7. Profit/ Loss(-) for the period (5-/+6)	187.48	10.13	889.30	1,375.20	2,166.42	1,967.94
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	-	-	1.90	-	1.90	14.96
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	1.90	-	1.90	14.96
9. Total comprehensive income for the period	187.48	10.13	891.20	1,375.20	2,168.32	1,982.90
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)	-	-	-	-	-	16,076.09
12. Debenture Redemption Reserve	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	0.89	0.05	4.24	6.54	10.31	9.42

Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- The Statement includes the financial results for the quarter and Nine Months ended 31st December, 2025 being the balancing figure between unaudited figures in respect of the financial year and the published unaudited year to date figure up to the third quarter of the current financial year which were subject to limited review by the auditors.

Place: Indore
Date: Feb 11, 2026



By order of the board
For Alpa Laboratories Limited
Mahendra Singh Chawla
Mahendra Singh Chawla
Director

C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F. C. A.

VIPUL PADLIYA B. Com., F. C. A.



H.O. : 90, Dawa Bazar, 2nd Floor, 13-14
RNT Marg, Indore - 452 001 (INDIA)
Office : +91 731 2704343

B.O. : 101, Pragati Appartment, Opp. Krashi
Mandi, Pratapnagar (Raj.)-312605

Tel. : +1478-22624

Official webpage : www.chpadliya.com

Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to Regulations 33 of the SEBI (LISTING Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of **ALPA LABORATORIES LIMITED,**

1. We have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** ("the Holding Company") and its subsidiary ("the Holding company and its subsidiary together referred as "the Group") for the quarter ended 31st December, 2025 and the period from 1st April, 2025 to 31st December, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations"), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles accepted in India is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial information performed by the independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations (As amended), to the extent applicable.

4. The Statement includes the results of the following entities:

1) Subsidiary:

A. Norfolk Mercantile Private Limited



C. H. PADLIYA & CO.

CHARTERED ACCOUNTANTS

A. K. PADLIYA M. Com., LL.B., F.C.A.

S. C. PADLIYA M. Com., F. C. A.

VIPUL PADLIYA B. Com., F. C. A.



H.O. : 90, Dawa Bazar, 2nd Floor, 13-14
RNT Marg, Indore - 452 001 (INDIA)

Office : +91 731 2704343

B.O. : 101, Pragati Appartment, Opp. Krashi
Mandi, Pratapnagar (Raj.)-312605

Tel. : +1478-22624

Official webpage : www.chpadliya.com

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes interim financial information of subsidiary which have been reviewed by us, whose interim financial information reflect total revenues of INR Nil lakhs and INR Nil lakhs, total net loss (after eliminating intercompany transactions) of INR 3.42 lakhs and INR 3.42 lakhs and total comprehensive profit (after eliminating intercompany transactions) of INR 3.42 lakhs and INR 3.42 lakhs for the quarter ended 31st December, 2025 and for the period from 1st April, 2025 to 31st December, 2025, respectively as considered in the Statement. These interim financial results have been reviewed by us and our conclusion in so far as it relates to the amounts and disclosure included of the subsidiary is based on our review and the procedures performed by us as stated in paragraph 3 above.

For & on behalf of

C.H. PADLIYA & CO.

Chartered Accountants

Firm registration no.003151C

S.C. PADLIYA

Partner

Membership No. 071666

UDIN: 26071666VJAFEW9747

Date: 11th Day of February, 2026

Place: Indore





Alpa Laboratories Ltd.

33/2 A.B. Road, Pigdamber-453446, Distt. Indore (M.P.) India
Phone No. +91-731-429 4567 Fax No. +91-731-429 4444. E-mail: cs.alpalabs@gmail.com
CIN: L85195MP1988PLC004446

Financial Results for Quarter and Nine Months ended 31st December, 2025 (Rs. in lacs except EPS)

II. Statement of Profit and Loss - Consolidated

Particulars	Consolidated Results					
	Quarter Ended			Nine Months Ended		Year Ended
	Dec-25	Sep-25	Dec-24	Dec-25	Dec-24	Mar-25
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a) Revenue from Operations	2,904.58	2,625.75	2,615.02	7,441.40	7,253.26	11,245.19
b) Other Income	91.10	305.97	880.17	1,591.54	2,087.15	2,334.77
Total income from operations	2,995.68	2,931.72	3,495.19	9,032.94	9,340.41	13,579.96
2. Expenses						
a) Cost of materials consumed	1,809.07	1,662.17	1,273.98	4,665.58	3,905.93	7,071.93
b) Purchases of stock-in-trade	2.07	1.16	48.42	3.23	90.72	93.11
c) Changes in inventories of finished products, work in progress and stock in trade	128.44	325.73	127.98	359.01	256.57	(145.23)
d) Employee benefit expenses	371.79	362.05	336.11	1,076.37	1,006.36	1,438.54
e) Finance costs	2.74	3.43	9.03	10.93	19.28	23.18
f) Depreciation and amortization expense	64.65	67.15	55.05	187.13	162.11	220.24
g) Other expenses						
Manufacturing & Operating	217.50	153.50	167.63	540.48	477.00	626.69
Others	224.73	345.28	586.61	827.49	1,061.77	1,684.81
Total expenses	2,820.98	2,920.47	2,604.81	7,670.22	6,979.74	11,013.27
3. Profit/(Loss) before exceptional items and tax (1-2)	174.70	11.25	890.38	1,362.72	2,360.67	2,566.69
4. Exceptional Items	-	-	-	-	(3.69)	-
5. Profit/ Loss(-) before tax (3+/-4)	174.70	11.25	890.38	1,362.72	2,364.36	2,566.69
6. Tax (Expenses)/ Benefit						
Current tax	(15.59)	-	-	(15.59)	196.63	(406.63)
Deferred Tax	-	-	-	-	-	(209.75)
Tax Related to Earlier Years	-	-	0.20	-	-	-
7. Profit/ Loss(-) for the period (5+/-6)	190.29	11.25	890.18	1,378.31	2,167.73	1,950.31
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	-	-	(0.18)	-	(0.18)	14.96
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	(0.18)	-	(0.18)	14.96
9. Total comprehensive income for the period	190.29	11.25	890.00	1,378.31	2,167.55	1,965.27
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)						15,039.35
12. Debenture Redemption Reserve						
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	0.90	0.05	4.23	6.55	10.30	9.34

Notes -

- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.
- The Statement includes the financial results for the quarter and half year ended 31st December, 2025 being the balancing figure between unaudited figures in respect of the financial year and the published unaudited year to date figure up to the third quarter of the current financial year which were subject to limited review by us.

Place: Indore
Date: Feb 11, 2026



By order of the board
For Alpa Laboratories Limited

Mahendra

Mahendra Singh Chawla
Director